DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Semaglutide (Ozempic). Adults with type 2 diabetes and high cardiovascular risk.
First occurrence of CV death, non-fatal MI, or non-fatal stroke.
26% relative risk reduction in major adverse cardiovascular events (HR 0.74, 95% CI 0.58-0.95). Established CV benefit class label.
Adults with type 2 diabetes and high cardiovascular risk.
Once-weekly subcutaneous semaglutide 0.5 or 1.0 mg vs placebo.
First occurrence of CV death, non-fatal MI, or non-fatal stroke.
26% relative risk reduction in major adverse cardiovascular events (HR 0.74, 95% CI 0.58-0.95). Established CV benefit class label.
Marso SP et al, NEJM 2016;375:1834-1844